Jazz Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jazz Pharmaceuticals (JAZZ).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

18Buy

2Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$263Upside to Avg. PT+11.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$325
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$337
Sep 11, 2026	UBS	Ashwani Verma	PT Raise	Buy	$315→$337
Sep 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$270→$271
Aug 26, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$287→$300
Aug 26, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$283→$322
Aug 26, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$264→$281
Aug 26, 2026	Needham	Ami Fadia	PT Raise	Buy	$292→$310
Aug 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$280→$283
Aug 4, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$265→$276
Aug 4, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$254→$264
Aug 4, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300
Aug 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$301→$310
Aug 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$285→$300
Aug 4, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$245→$280
Aug 4, 2026	Needham	Ami Fadia	PT Raise	Buy	$282→$292
Aug 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$260→$270
Aug 4, 2026	Baird	Joel Beatty	PT Raise	Outperform	$252→$280
Jul 20, 2026	Needham	Ami Fadia	PT Raise	Buy	$255→$282
Jul 17, 2026	Canaccord Genuity	Gary Nachman	Initiate	Buy	$290

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.

Benzinga Newsdesk

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.

Avi Kapoor

Jazz Pharmaceuticals PLC

ニュース

パートナーシップ

ベンジンガ・グローバル

Jazz Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

People Also Watch

People Also Watch

Jazz Pharmaceuticals PLC

ニュース

パートナーシップ

ベンジンガ・グローバル

Jazz Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PROUBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PROBarclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

PRODeutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

PROMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

People Also Watch

People Also Watch

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322